Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31432452 | 0.94 | GAA (0.48) | GAASMN1; SMN2HPGDCYP1A2CYP3A4 | |
| SCHEMBL5470003 | 0.86 | ALDH1A1 (0.46) | GAASMN1; SMN2HPGDKDM4ELMNA | |
| SCHEMBL8902218 | 0.85 | GAA (0.55) | GAASMN1; SMN2HPGDCYP1A2CYP3A4 | |
| SCHEMBL23604413 | 0.83 | GAA (0.56) | GAASMN1; SMN2HPGDCYP1A2CYP3A4 | |
| SCHEMBL15544098 | 0.83 | GAA (0.52) | GAASMN1; SMN2HPGDCYP1A2CYP3A4 | |
| SCHEMBL30373029 | 0.83 | GAA (0.52) | GAASMN1; SMN2HPGDCYP1A2CYP3A4 | |
| SCHEMBL410466 | 0.82 | GAA (0.48) | GAASMN1; SMN2HPGDCYP1A2CYP3A4 | |
| SCHEMBL23704095 | 0.81 | GAA (0.54) | GAASMN1; SMN2HPGDCYP3A4KDM4E | |
| SCHEMBL4728790 | 0.81 | GAA (0.48) | GAASMN1; SMN2HPGDCYP1A2CYP3A4 | |
| SCHEMBL25382065 | 0.81 | GAA (0.48) | GAASMN1; SMN2HPGDCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161631-A1 | Substituted Phenoxyacetic Acids | PHARMACIA & UPJOHN COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161631-A1 | Substituted Phenoxyacetic Acids | PHARMACIA & UPJOHN COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-7189749-B2 | Substituted phenoxyacetic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189749-B2 | Substituted phenoxyacetic acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050239849-A1 | Useful for therapy of chronic complications arising from diabetes, such as neuropathy; may also contain an angiotensin converting enzyme inhibitor | THE INSTITUTES OF PHARMACEUTICAL DISCOVERY LLC. (US) | 2005-10-27 | — | — | US | disclosed |
| US-20030036558-A1 | Substituted phenoxyacetic acids | THE INSTITUTES OF PHARMACEUTICAL DISCOVERY LLC. | 2003-02-20 | — | — | US | disclosed |
| US-6420426-B1 | USED TO TREAT COMPLICATIONS FROM DIABETES MELLITUS | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2002-07-16 | — | — | US | disclosed |
| EP-1198451-A2 | SUBSTITUTED PHENOXYACETIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001000566-A2 | SUBSTITUTED PHENOXYACETIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161631-A1 | Substituted Phenoxyacetic Acids | SLC5A2, GPR119, SLC5A1 | GAA 48/4885SMN1; SMN2 3384/4885HPGD 830/4885 |
| US-20050239849-A1 | Useful for therapy of chronic complications arising from diabetes, such as neuropathy; may also contain an angiotensin converting enzyme inhibitor | ACE, DNPEP, AGT | GAA 79/4885SMN1; SMN2 811/4885HPGD 125/4885 |
| US-20030036558-A1 | Substituted phenoxyacetic acids | SLC5A2, GPR119, SLC5A1 | GAA 48/4885SMN1; SMN2 3384/4885HPGD 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.